We now have a number of procedures and devices that we can implement in people with Parkinson’s when they develop motor complications. Generally, we identify them by a very simple criteria, which is five hours of OFF time or five intakes of levodopa or two hours OFF time or one hour with dyskinesias. This 5-2-1 criteria, it has been used now broadly to identify people who may be suitable for advanced therapies...
We now have a number of procedures and devices that we can implement in people with Parkinson’s when they develop motor complications. Generally, we identify them by a very simple criteria, which is five hours of OFF time or five intakes of levodopa or two hours OFF time or one hour with dyskinesias. This 5-2-1 criteria, it has been used now broadly to identify people who may be suitable for advanced therapies. Infusion therapies have undergone an important development in recent years, as we have been able in the last two, three years to use subcutaneous levodopa delivery for 24 hours. I think the main advances that we have seen in this field regard the fact that we can provide the levodopa delivery throughout the night and that we can improve significantly the quality of sleep. People with Parkinson’s can wake up better and we can replace the total amount of oral levodopa by a subcutaneous infusion which lets people be more stable. It helps them reduce off time and extend the good mobility time throughout the day.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.